US Patent Office sides with Merck & Co on validity of Singulair patent
This article was originally published in Scrip
Executive Summary
A key patent held by Merck & Co will stand despite a challenge by an outside group that had raised new questions on its patentability. Merck said that the US Patent and Trademark Office has agreed with its arguments regarding the validity of patent No 5,565,473 covering the active ingredient of its top-selling asthma drug Singulair (montelukast sodium).